Pfizer CEO Sees China as Major Rival by 2030

Albert Bourla said at a London healthcare conference that China's biotech ambitions make it a growing competitor to Pfizer.

Updated on Nov. 17, 2026 in Biotech

Photograph of a row of stainless-steel bioreactor vessels and clean pipework in a bright pharmaceutical production hall.
Pfizer CEO Albert Bourla told a London healthcare conference on 17 November that China's growing biotech sector will be the company's major competition by 2030. AI Illustration. Upload story photo >

Live Poll

Do you think American medicine prices will get better or worse over the next decade?

Pfizer CEO Albert Bourla said at the Jefferies Global Healthcare Conference in London on 17 November that China is growing its biotech business and has an ambition to become a global player. He forecast that Chinese companies will be Pfizer's major competition by 2030.

Why it matters

China's government has set out a plan to lead global drug innovation, shifting from supplying active pharmaceutical ingredients to exporting new medicines. Licensing deals between US and Chinese drugmakers have grown significantly, raising questions about competition and US policy toward Chinese biotech.

China's government 15th five-year biomedical plan targets 25% of global first-in-class drugs by 2030, while Bourla says Pfizer must become 3-4 times faster and operate at half the cost of Chinese competitors. How these targets will be tracked and whether they will be met has not been established.

The players

Albert Bourla

Chief executive of Pfizer, one of the world's largest pharmaceutical companies, who leads the company's global research and commercial operations.

Pfizer

A multinational pharmaceutical company headquartered in New York that develops and sells medicines and vaccines worldwide.

The details

Bourla spoke at the Jefferies conference in London, pointing to China's growing biotech sector and its ambition to become a global player. In September, China unveiled its 15th five-year biomedical plan, which seeks to make the country an exporter of innovative drugs rather than a supplier of active pharmaceutical ingredients.

Timeline

  1. January 2026: AstraZeneca signed an $18.5bn obesity deal with CSPC.

  2. September 2026: China unveiled its 15th five-year biomedical plan.

  3. October 2026: The US Treasury proposed adding biotech to the COINS Act.

  4. November 17, 2026: Bourla made his China competition remarks in London.

  5. November 2026: Democrats won both the Senate and House in US midterm elections.

Legacy Frame

China's 2030 biomedical target arrives as the BIOSECURE Act restricts Chinese biotechs' access to US federal funds and partnerships. Licensing deals such as AstraZeneca's $18.5bn obesity agreement with CSPC show that cross-border drug collaboration continues despite those limits.

Patients may see new drugs from international developers as licensing deals increase. Restrictions tied to the BIOSECURE Act could affect which medicines reach the US market and how quickly they arrive.

The takeaway

Cross-border drug partnerships are expanding even as governments tighten rules on them. Readers following pharmaceutical markets should watch how US policy and China's 2030 targets shape which medicines are developed and sold.

Further reading

For broader coverage of drug development and industry shifts, see Biotech.

Live Poll

Do you think American medicine prices will get better or worse over the next decade?